Simon Daniel van Haren (Simon D van Haren, Ross England, Simon D van Haren)

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 18

Top Venues

Harvard Medical School

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Harvard Medical School Nov 01 2018

United States

Instructor :: Pediatrics

Boston Children's Hospital Apr 01 2012 - Oct 31 2018

United States

Research Fellow :: Division of Infectious Diseases

Sanquin Research Jun 01 2006 - Dec 23 2011

Netherlands

Ph.D. candidate :: Plasma Proteins

Publications

Julie Zimmermann, Simon Daniel van Haren, Joann Diray-Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Author Correction: Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 9 (1) (2024)
Dheeraj Soni, Francesco Borriello, David A Scott, Frederic Feru, Maria De Leon, Spencer E Brightman, Wing Ki Cheng, Gandolina Melhem, Jennifer A Smith, Juan C Ramirez, Soumik Barman, Michael D Cameron, Aisling Kelly, Kristina Walker, Etsuro Nanishi, Simon Daniel van Haren, Tony Phan, Yizhi Qi, Robert Kinsey, Michal M Rączy, Al Ozonoff, Matthew A Pettengill, Jeffrey A Hubbell, Christopher B Fox, David J Dowling, Ofer Levy
From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation. Science advances 10 (27) (2024)
Dheeraj Soni, Francesco Borriello, David A Scott, Frederic Feru, Maria De Leon, Spencer E Brightman, Wing Ki Cheng, Gandolina Melhem, Jennifer A Smith, Juan C Ramirez, Soumik Barman, Michael D Cameron, Aisling Kelly, Kristina Walker, Etsuro Nanishi, Simon Daniel van Haren, Tony Phan, Yizhi Qi, Robert Kinsey, Michal M Rączy, Al Ozonoff, Matthew A Pettengill, Jeffrey A Hubbell, Christopher B Fox, David J Dowling, Ofer Levy
From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation. Science advances 10 (27) (2024)
Dheeraj Soni, Francesco Borriello, David A Scott, Frederic Feru, Maria De Leon, Spencer E Brightman, Wing Ki Cheng, Gandolina Melhem, Jennifer A Smith, Juan C Ramirez, Soumik Barman, Michael D Cameron, Aisling Kelly, Kristina Walker, Etsuro Nanishi, Simon Daniel van Haren, Tony Phan, Yizhi Qi, Robert Kinsey, Michal M Rączy, Al Ozonoff, Matthew A Pettengill, Jeffrey A Hubbell, Christopher B Fox, David J Dowling, Ofer Levy
From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation. Science advances 10 (27) (2024)
Julie Zimmermann, Simon Daniel van Haren, Joann Diray-Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Author Correction: Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 9 (1) (2024)
Julie Zimmermann, Simon Daniel van Haren, Joann Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 8 (1) (2023)
Julie Zimmermann, Simon Daniel van Haren, Joann Diray-Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 8 (1) (2023)
Julie Zimmermann, Simon Daniel van Haren, Joann Diray-Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 8 (1) (2023)
Julie Zimmermann, Simon Daniel van Haren, Joann Diray-Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 8 (1) (2023)
Julie Zimmermann, Simon Daniel van Haren, Joann Diray-Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 8 (1) (2023)
Simon Doss-Gollin, Sanya Thomas, Byron Brook, Kimia Abedi, Célia Lebas, Floriane Auderset, Yamile Lugo-Rodriguez, Guzmán Sanchez, David J Dowling, Ofer Levy, Simon Daniel van Haren
Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen. NPJ vaccines 8 (1) (2023)
Julie Zimmermann, Simon Daniel van Haren, Joann Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 8 (1) (2023)
Elisabeth M S Beijnen, Oludare A Odumade, Simon Daniel van Haren
Molecular Determinants of the Early Life Immune Response to COVID-19 Infection and Immunization. Vaccines 11 (3) (2023)
Elisabeth M S Beijnen, Oludare A Odumade, Simon Daniel van Haren
Molecular Determinants of the Early Life Immune Response to COVID-19 Infection and Immunization. Vaccines 11 (3) (2023)
Simon Daniel van Haren, Gabriel K Pedersen, Azad Kumar, Tracy J Ruckwardt, Syed Moin, Ian N Moore, Mahnaz Minai, Mark Liu, Jensen Pak, Francesco Borriello, Simon Doss-Gollin, Elisabeth M S Beijnen, Saima Ahmed, Michaela Helmel, Peter Andersen, Barney S Graham, Hanno Steen, Dennis Christensen, Ofer Levy
CAF08 adjuvant enables single dose protection against respiratory syncytial virus infection in murine newborns. Nature communications 13 (1) (2022)
Katherine Chew, Branden Lee, Simon Daniel van Haren, Etsuro Nanishi, Timothy R O'Meara, Jennifer B Splaine, Maria DeLeon, Dheeraj Soni, Hyuk-Soo Seo, Sirano Dhe-Paganon, Al Ozonoff, Jennifer A Smith, Ofer Levy, David J Dowling
Adjuvant Discovery via a High Throughput Screen using Human Primary Mononuclear Cells. bioRxiv : the preprint server for biology (2022)
Simon Daniel van Haren, Jensen Pak, Mark Liu, Shun Rao, Al Ozonoff, Ofer Levy
Human Blood Plasma Shapes Distinct Neonatal TLR-Mediated Dendritic Cell Activation via Expression of the MicroRNA Let-7g. ImmunoHorizons 5 (4) (2021)
Simon Daniel van Haren, David J Dowling, Willemina Foppen, Dennis Christensen, Peter Andersen, Steven G Reed, Robert M Hershberg, Lindsey R Baden, Ofer Levy
Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization. Journal of immunology (Baltimore, Md. : 1950) 197 (11) (2016)

Simon Daniel van Haren.css-eqlu8i{font-size:small;padding-left:4px;} (Simon D van Haren, Ross England, Simon D van Haren)

Publication Activity (10 Years)

Top Topics

Top Venues

Simon Daniel van Haren (Simon D van Haren, Ross England, Simon D van Haren)